Homepage Top Section1

The company was created after the acquisition of Alexion Pharmaceuticals by AstraZeneca last year. The aim of the acquisition is to expedite the expansion of Alexion into genomic

Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are

Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization

Terlivaz is claimed to be the first and only FDA-approved product that is indicated for improving kidney function in HRS adult patients with quick kidney function reduction. The

Recently, the company announced, EVX-B2, a new discovery project to develop a vaccine candidate for gonorrhea using EDEN, its artificial intelligence (AI) platform. In addition to UMass Chan’s

The vaccine has been authorised for use in adolescents aged 12 to 17 years. The protein-based vaccine, Nuvaxovid is engineered from the genetic sequence of the initial SARS-CoV-2

The latest move comes after the receipt of the US Food and Drug Administration (FDA) approval in May this year for the new formulation, which includes the same

The plant-derived small molecule, tigilanol tiglate targets various solid tumours across multiple species. The drug is being developed as an intratumoural treatment for solid tumours. It has a

Applying Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology, the partnership intends to develop intravitreal AAV capsids matching a capsid profile defined by Roche. As per the